<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Differences in BDNF and ΔFosB levels in Wistar-Kyoto and Wistar rats</dc:title><dc:creator>Banjac,	Anamarija	(Avtor)
	</dc:creator><dc:creator>Živin,	Marko	(Vodja projekta)
	</dc:creator><dc:creator>Zorović,	Maja	(Mentor)
	</dc:creator><dc:subject>Wistar-Kyoto rat</dc:subject><dc:subject>brain-derived neurotrophic factor</dc:subject><dc:subject>BDNF</dc:subject><dc:subject>ΔFosB</dc:subject><dc:subject>anhedonia</dc:subject><dc:subject>addiction</dc:subject><dc:description>The Wistar-Kyoto (WKY) rat strain is a model for treatment-resistant depression, exhibiting behaviours indicative of anhedonia. The strain also displays disruptions in neurochemical signalling, typical in patients with anhedonia. According to the Neurotrophic hypothesis of depression, BDNF is the main plasticity protein involved in the pathophysiology of depression. However, levels of brain-derived neurotrophic factor (BDNF) have not yet been investigated in WKY rats. To investigate this in the framework of anhedonia, WKY rats and control Wistar (W) rats were repeatedly treated with amphetamine (AMPH) and morphine (MORPH). After measuring behavioural readouts, rats were sacrificed, their brains isolated, and frozen. Brain tissue was sectioned, and three regions of interest were assessed: prefrontal cortex (PFC), nucleus accumbens (NAc), and ventral tegmental area (VTA). BDNF was assessed as a molecular marker for anhedonia. To check if any molecular processes of addiction were involved, levels of ΔFosB were measured. Both proteins of interest were first assessed with Western Blot (WB). Bdnf mRNA-positive cells were additionally assessed with in-situ hybridization (ISH). ΔFosB-immunoreactive cells were further assessed with immunohistochemistry (IHC). WB showed elevated BDNF protein expression in all three regions of interest in WKY rats. WKY rats also exhibited an increase in Bdnf mRNA-positive cells in the PFC, as indicated by ISH. For ΔFosB, AMPH affected ΔFosB levels only in the PFC of W rats, indicated by WB. In IHC, no specific treatment affected ΔFosB levels, but WKY rats showed higher overall expression compared to W rats. The results show line differences in BDNF in areas typically involved in disordered reward-processing. Reliable molecular processes of addiction were not found.</dc:description><dc:date>2026</dc:date><dc:date>2026-05-11 10:47:54</dc:date><dc:type>Neznano</dc:type><dc:identifier>182417</dc:identifier><dc:language>sl</dc:language></metadata>
